Table 1.

Therapeutic effects of oral administration of the dual analog on an established clinical EAMG in mice

Treatment	No. of mice
	Total	Remission or improvement	Sick	Dead
Dual analog	31	23 (74%)	7 (23%)	1 (3%)
PBS	20	7 (35%)	8 (40%)	5 (25%)

C57BL/6 mice were immunized and boosted with Torpedo AChR in CFA (see Materials and Methods). After the mice developed clinical EAMG, they were randomly divided into two groups. One group was treated with the dual analog (Lys-262–Ala-207, 500 μg per mouse administered orally in PBS, three times per week), and the second group was treated with PBS. Disease manifestations were determined according to disease score, grip strength measurements, and electromyography (see Materials and Methods). The above results are of three alike experiments. χ² was used to analyze differences between the dual analog- and PBS-treated groups for all categories (P = 0.0094).